Skip to main content
. 2018 Dec 7;58(4):683–691. doi: 10.1093/rheumatology/key352

Fig. 2.

Fig. 2

Sensitivity analyses for the risk of cancer associated with abatacept as the initial bDMARD compared with other bDMARDs (primary objective)

bDMARD: biologic DMARD; HR: hazard ratio.